Mesoblast/$MESO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mesoblast
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Ticker
$MESO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Melbourne, Australia
Employees
73
ISIN
US5907174016
Website
Mesoblast Metrics
BasicAdvanced
$1.4B
-
-$0.09
2.13
-
Price and volume
Market cap
$1.4B
Beta
2.13
52-week high
$22.00
52-week low
$5.78
Average daily volume
209K
Financial strength
Current ratio
0.958
Quick ratio
0.563
Long term debt to equity
23.029
Total debt to equity
27.34
Interest coverage (TTM)
-2.43%
Profitability
EBITDA (TTM)
-49.425
Gross margin (TTM)
-370.20%
Net profit margin (TTM)
-1,822.77%
Operating margin (TTM)
-906.03%
Effective tax rate (TTM)
-0.12%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-4.85%
Return on equity (TTM)
-21.31%
Valuation
Price to revenue (TTM)
2,309.82
Price to book
4.17
Price to tangible book (TTM)
-16.94
Price to free cash flow (TTM)
-306.141
Free cash flow yield (TTM)
-0.33%
Free cash flow per share (TTM)
-3.82%
Growth
Revenue change (TTM)
-24.07%
Earnings per share change (TTM)
7.13%
3-year revenue growth (CAGR)
-16.86%
10-year revenue growth (CAGR)
-13.26%
3-year earnings per share growth (CAGR)
-15.43%
10-year earnings per share growth (CAGR)
-9.99%
What the Analysts think about Mesoblast
Analyst ratings (Buy, Hold, Sell) for Mesoblast stock.
Bulls say / Bears say
The FDA granted Rare Pediatric Disease designation to Mesoblast's Revascor for treating children with congenital heart disease, potentially leading to a Priority Review Voucher upon approval. (nasdaq.com)
Mesoblast was added to the S&P/ASX 200 Index, enhancing its visibility and credibility among investors. (stocktitan.net)
The FDA indicated a favorable view on Mesoblast's plans to seek U.S. approval for its cell therapy candidate remestemcel-L, boosting investor confidence. (seekingalpha.com)
Mesoblast reported a net loss of $88.0 million for the fiscal year ended June 30, 2024, a 7% increase from the previous year, raising concerns about its financial health. (nasdaq.com)
The FDA issued a Complete Response Letter for Mesoblast's remestemcel-L, requesting additional data before approval, leading to a significant stock price decline. (fool.com)
Mesoblast's commercialization revenue decreased by 21% in the fiscal year ended June 30, 2024, indicating potential challenges in product adoption. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Mesoblast Financial Performance
Revenues and expenses
Mesoblast Earnings Performance
Company profitability
Mesoblast News
AllArticlesVideos
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
GlobeNewsWire·1 week ago
FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
GlobeNewsWire·1 month ago
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mesoblast stock?
Mesoblast (MESO) has a market cap of $1.4B as of June 20, 2025.
What is the P/E ratio for Mesoblast stock?
The price to earnings (P/E) ratio for Mesoblast (MESO) stock is 0 as of June 20, 2025.
Does Mesoblast stock pay dividends?
No, Mesoblast (MESO) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Mesoblast dividend payment date?
Mesoblast (MESO) stock does not pay dividends to its shareholders.
What is the beta indicator for Mesoblast?
Mesoblast (MESO) has a beta rating of 2.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.